Retatrutide 15mg
Retatrutide (LY3437943) is an investigational triple receptor agonist targeting the GIP, GLP-1, and glucagon receptors. The addition of glucagon-receptor agonism distinguishes it from dual agonists and is studied in models of hepatic lipid oxidation and energy-metabolism signaling. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.
Strength
Select Option
2+ save 5% · 5+ save 10% · 10+ save 20%
- Free Priority shipping on US orders over $100
- Ships same day on orders before 2 PM MST
- Discreet, unmarked packaging
- Third-party tested — lot RET-20260811-02 at 99.68% purity
Batch Tracking
Batch #
RET-20260811-02
Tested
2026-08-23
Purity
99.68%
Method
RP-HPLC (214 nm)
Mechanism of Action
Retatrutide activates three class B GPCRs — GLP-1R, GIPR, and the glucagon receptor (GCGR). In research models, GCGR engagement is studied for hepatic fatty-acid oxidation, amino-acid catabolism, and energy-metabolism signaling alongside incretin-receptor pathways.
Properties
CAS Number
2381089-83-2
Molecular Formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight
4731.33 Da
Half-Life
~6 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Shipping & Delivery
- Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
- US shipping from $5. Free Priority on orders $100+ (before discounts).
- Plain, unmarked packaging — no branding or product names on the outside.
- Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Quality & Testing
- Independently tested by Bioviridian Inc. — identity by LC-MS/MS, purity by RP-HPLC (214 nm).
- Measured at 99.68% purity on lot RET-20260811-02.
- USA-based; dispatched from Phoenix, Arizona.
- Supplied strictly for in-vitro laboratory research — not for human use.
Research Applications
References & Citations
(2)Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias JP, Jastreboff AM, et al.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS, Welch M, Shah P, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.